Hypertension is Associated with Serologically Active Disease in Patients with Systemic Lupus Erythematosus: Role of Increased Th1/Th2 Ratio and Oxidative Stress
Overview
Authors
Affiliations
Objectives: To determine whether disease activity verified by laboratorial parameters is associated with a higher frequency of hypertension in patients with systemic lupus erythematosus (SLE) without renal impairment and to investigate factors that could influence this hypertension.
Method: This study included 102 controls, 70 patients with inactive SLE, and 53 patients with active SLE without renal impairment. We evaluated T helper type 1 (Th1)/Th2 lineage cytokines, nitric oxide (NO), insulin resistance (IR), and oxidative stress.
Results: Patients with active SLE had a higher probability of developing hypertension compared to controls [odds ratio (OR) 3.833, 95% confidence interval (CI) 1.806-8.137, p < 0.0003] and patients with inactive SLE (OR 2.215, 95% CI 1.032-4.752, p = 0.0394). Active SLE patients had a higher interleukin (IL)-12/IL-4 ratio (p < 0.05) than both controls and inactive SLE patients. Protein oxidation was significantly higher in patients with active SLE than in the control group and in patients with inactive SLE (p < 0.01 and p < 0.05, respectively). Multivariate analysis revealed an association between the presence of hypertension and he levels of glucose (p = 0.0276), insulin (p = 0.0498), hydroperoxides (p = 0.0221), IFN-γ (p = 0.0494), IL-17 (p = 0.0272), IL-12/IL-10 (p = 0.0373), IFN-γ/IL-10 (p = 0.0142), IFN-γ/IL-4 (p = 0.0320), and adiponectin (p = 0.0433).
Conclusions: Patients with active SLE without renal impairment had an increased frequency of high blood pressure (43.4%) compared with patients with inactive SLE (25.7%) and controls (16.7%). Hypertension was associated with serologically active disease and was influenced by an increased Th1/Th2 ratio and oxidative stress.
The Role of the Oxidative State and Innate Immunity Mediated by TLR7 and TLR9 in Lupus Nephritis.
Echavarria R, Cardona-Munoz E, Ortiz-Lazareno P, Andrade-Sierra J, Gomez-Hermosillo L, Casillas-Moreno J Int J Mol Sci. 2023; 24(20).
PMID: 37894915 PMC: 10607473. DOI: 10.3390/ijms242015234.
Ketkar H, Alqahtani M, Tang S, Parambath S, Bakshi C, Jain S Front Microbiol. 2023; 14:1173577.
PMID: 37266014 PMC: 10229887. DOI: 10.3389/fmicb.2023.1173577.
Yan Z, Chen Q, Xia Y J Inflamm Res. 2023; 16:453-465.
PMID: 36761905 PMC: 9907008. DOI: 10.2147/JIR.S399284.
Autoimmune-mediated renal disease and hypertension.
Boesen E, Kakalij R Clin Sci (Lond). 2021; 135(17):2165-2196.
PMID: 34533582 PMC: 8477620. DOI: 10.1042/CS20200955.
Yin R, Xu R, Ding L, Sui W, Niu M, Wang M Biomed Res Int. 2021; 2021:9952463.
PMID: 34337065 PMC: 8318742. DOI: 10.1155/2021/9952463.